Random mutagenesis and phage display technology as a tool for identifying ige epitopes of the birch pollen allergen Bet v 1 by Elisabeth Guhsl et al.
ORAL PRESENTATION Open Access
Random mutagenesis and phage display
technology as a tool for identifying ige epitopes
of the birch pollen allergen Bet v 1
Elisabeth Eva Guhsl1*, Gerlinde Hofstetter1, Christof Ebner2, Wolfgang Hemmer3, Heimo Breiteneder1,
Christian Radauer1
From 5th International Symposium on Molecular Allergology (ISMA 2013)
Vienna, Austria. 6-7 December 2013
Background
IgE-binding epitopes of the major birch pollen allergen Bet
v 1 are dependent on the native structure of the allergen.
To date, only a single IgE epitope has been identified. We
aimed to identify additional epitopes by directed in vitro
evolution of non-IgE-binding structural homologues to
proteins carrying single IgE-binding patches. For that pur-
pose, we chose cytokinin-specific binding protein (CSBP)
from Vigna radiata (mung bean), a structural homologue
of Bet v 1 with only 31% sequence identity, as a template
subjected to a combination of random mutagenesis and
phage display.
Methods
CSBP was expressed in Escherichia coli and purified by
chromatographic methods. The protein integrity was veri-
fied by SDS-PAGE, mass spectrometry and circular
dichroism and IgE binding assessed by ELISA using sera
from a panel of birch pollen allergic patients. Random
mutagenesis of CSBP was performed by PCR using muta-
genic nucleotide analogues. Phage display libraries of ran-
domly mutated CSBP were created in the filamentous
phage M13 by inserting PCR products into the phagmid
pTP127. Biopanning was performed for selecting phages
with binding activity to birch pollen allergic patients’ IgE.
After each panning round, an additional mutagenesis was
performed and a new library created. IgE binding activities
of enriched phages and of bacterial colonies representing
single clones were analysed by transfer to nitrocellulose
and immunostaining.
Results
Purified recombinant CSBP revealed a secondary structure
with high similarity to that of Bet v 1, but only low IgE
binding in 11 of 35 sera from Bet v 1-sensitised birch pol-
len allergic patients. Phage libraries CSBPm1, CSBPm2
and CSBPm3 with diversities of 105-107 different clones
were created. Sequencing of 19 randomly picked clones
from the unselected CSBPm1 library showed an average
mutation rate of 5% (range 2.5-11.5). Analysis of single
clones from the first two panning rounds yielded clones
which expressed IgE binding mutant proteins.
Conclusion
Directed in vitro evolution of CSBP by random muta-
genesis of surface residues might be a suitable tool for
defining conformational IgE binding epitopes of the
birch pollen allergen Bet v 1.
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